BlackRock
AKCA

BlackRock’s Akcea Therapeutics Inc AKCA Stock Holding History

BlackRock’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,201,538
Closed -$39.9M – 5274
2020
Q3 		$39.9M Sell
2,201,538
-100,698
-4% -$1.43M ﹤0.01% 2427
2020
Q2 		$31.5M Buy
2,302,236
+490,512
+27% +$7.57M ﹤0.01% 2544
2020
Q1 		$25.9M Sell
1,811,724
-49,292
-3% -$809K ﹤0.01% 2470
2019
Q4 		$31.5M Sell
1,861,016
-63,446
-3% -$1.18M ﹤0.01% 2628
2019
Q3 		$29.6M Buy
1,924,462
+17,050
+0.9% +$363K ﹤0.01% 2591
2019
Q2 		$44.7M Buy
1,907,412
+21,377
+1% +$528K ﹤0.01% 2387
2019
Q1 		$53.4M Sell
1,886,035
-125,394
-6% -$3.65M ﹤0.01% 2237
2018
Q4 		$60.6M Buy
2,011,429
+113,784
+6% +$3.19M ﹤0.01% 2116
2018
Q3 		$66.5M Sell
1,897,645
-3,902
-0.2% -$118K ﹤0.01% 2225
2018
Q2 		$45.1M Buy
1,901,547
+121,184
+7% +$2.89M ﹤0.01% 2417
2018
Q1 		$45.6M Sell
1,780,363
-45,789
-3% -$986K ﹤0.01% 2316
2017
Q4 		$31.7M Buy
1,826,152
+988,200
+118% +$19.4M ﹤0.01% 2533
2017
Q3 		$23.2M Buy
+837,952
New +$15.5M ﹤0.01% 2723

BlackRock's AKCA Position: Q4 2020 in Review

BlackRock sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 2,201,538 shares — an estimated $39.9M sold.

BlackRock first reported a position in AKCA in Q3 2017 and held it in 13 quarters. The position peaked at $66.5M in Q3 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

  • BlackRock reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
  • BlackRock sold 2,201,538 Akcea Therapeutics Inc shares in Q4 2020, an estimated $39.9M.
  • BlackRock first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 13 quarters.
  • BlackRock's Akcea Therapeutics Inc position peaked at $66.5M in Q3 2018.
  • 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on BlackRock's 13F filing for Q4 2020, filed 5 Feb 2021.